2018
Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose
Ye Q, Wu J, Lu Y, Naganawa M, Gallezot JD, Ma T, Liu Y, Tanoue L, Detterbeck F, Blasberg J, Chen MK, Casey M, Carson RE, Liu C. Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose. Physics In Medicine And Biology 2018, 63: 175015. PMID: 30095083, PMCID: PMC6158045, DOI: 10.1088/1361-6560/aad97f.Peer-Reviewed Original ResearchConceptsPopulation-based input functionStandardized uptake valueImage-derived input functionLung nodulesClinical trialsTime-activity curvesLow-dose computed tomography (LDCT) screeningLung cancer mortality ratesIndeterminate lung nodulesComputed Tomography ScreeningF-FDG PETCancer mortality ratesStatic PET acquisitionVirtual clinical trialsScan durationTomography screeningFDG injectionPET scansMortality rateUptake valueAccurate diagnosisMalignant lung nodulesROC analysisPatient dataMalignant nodules
2017
Validating the Thoracic Revised Cardiac Risk Index Following Lung Resection
Thomas DC, Blasberg JD, Arnold BN, Rosen JE, Salazar MC, Detterbeck FC, Boffa DJ, Kim AW. Validating the Thoracic Revised Cardiac Risk Index Following Lung Resection. The Annals Of Thoracic Surgery 2017, 104: 389-394. PMID: 28499655, DOI: 10.1016/j.athoracsur.2017.02.006.Peer-Reviewed Original ResearchConceptsAdditional cardiac evaluationIschemic heart diseaseLarger multi-institutional datasetsCardiac complicationsLung resectionRenal comorbiditiesCardiac evaluationCerebrovascular diseaseHeart diseaseRisk factorsMulti-institutional datasetSurgeons National Surgical Quality Improvement Program datasetNational Surgical Quality Improvement Program datasetCardiac complication ratesMajor cardiac complicationsPreoperative risk factorsUnderwent pneumonectomyCardiac indexComplication ratePrimary outcomeRisk classesMalignant diseaseOpen procedureAmerican CollegeHigh risk
2012
Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population
Joseph S, Harrington R, Walter D, Goldberg JD, Li X, Beck A, Litton T, Hirsch N, Blasberg J, Slomiany M, Rom W, Pass H, Donington J. Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population. Cancer Biomarkers 2012, 12: 177-184. PMID: 23568008, PMCID: PMC3746829, DOI: 10.3233/cbm-130306.Peer-Reviewed Original ResearchConceptsIncident cancerPlasma osteopontinNon-small cell lung cancer careLung cancer careCase-control studySerial plasmaNSCLC patientsCT screeningSurveillance intervalsCancer careLung cancerPlasma levelsWilcoxon Signed Rank TestDisease statusCancerSigned Rank TestBenign nodulesSecreted phosphoproteinCTRank testOsteopontinEarly evidenceNSCLCPatientsNSCLCs